Sage Journals: Discover world-class research

Abstract

Limited effective treatment options currently exist for trichomoniasis management among patients with metronidazole hypersensitivity. We report a patient with a documented history of metronidazole hypersensitivity who initially was treated with nitazoxanide but demonstrated clinical and microbiological failure. Secnidazole was subsequently used for treatment, which resulted in clinical and microbiological cure without observation of cross-reactivity. Secnidazole may represent a potential treatment option for trichomoniasis in patients with metronidazole hypersensitivity after consultation with an infectious disease specialist.

Keywords

Secnidazole metronidazole trichomoniasis nitazoxanide

Get full access to this article

View all access options for this article.

References

Satterwhite

Torrone

Meites

, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013; 40(3): 187–193.

Meites

Gaydos

Hobbs

, et al. A review of evidence-based care of symptomatic trichomoniasis and asymptomatic trichomonas vaginalis infections. Clin Infect Dis 2015; 61(Suppl 8): S837–S848.

Van Gerwen

Camino

Bourla

, et al. Management of trichomoniasis in the setting of 5-nitroimidazole hypersensitivity. Sex Transm Dis 2020. Epub ahead of print.

Muzny

Van Gerwen

Kissinger

. Updates in trichomonas treatment including persistent infection and 5-nitroimidazole hypersensitivity. Curr Opin Infect Dis 2020; 33(1): 73–77.

Helms

Mosure

Secor

, et al. Management of trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008; 198(4): 370–377.

Thami

Kanwar

. Fixed drug eruption due to metronidazole and tinidazole without cross-sensitivity to secnidazole. Dermatology 1998; 196(3): 368.

Abdel-Magied

Hammouda

Mosbah

, et al. In vitro activity of nitazoxanide against some metronidazole-resistant and susceptible Trichomonas vaginalis isolates. J Infect Chemother 2017; 23(4): 230–233.

Dan

Sobel

. Failure of nitazoxanide to cure trichomoniasis in three women. Sex Transm Dis 2007; 34(10): 813–814.

Ghosh

Aycock

Schwebke

. In vitro study of the susceptibility of clinical isolates of Trichomonas vaginalis to metronidazole and secnidazole. Antimicrob Agents Chemother 2018; 62(4): e02329–e02417.

10.

BioSpace . Lupin Presents Phase 3 Data for Solosec (Secnidazole) Demonstrating Significant Response Rate in Female Patients with Trichomoniasis, 2020. Available at: https://www.biospace.com/article/releases/lupin-presents-phase-3-data-for-solosec-secnidazole-demonstrating-significant-response-rate-in-female-patients-with-trichomoniasis/

11.

Sanmukhani

Shah

Baxi

, et al. Fixed drug eruption with ornidazole having cross-reactivity to secnidazole but not to other nitroimidazole compounds: a case report. Br J Clin Pharmacol 2010; 69(6): 703–704.

12.

Metronidazole [package insert]. New York, NY: Pfizer; 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/12623slr059_flagyl_lbl.pdf

13.

Secnidazole [package insert]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209363s000lbl.pdf

14.

Tinidazole [package insert]. San Antonio, TX: Mission Pharmacal Company; 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021618s006lbl.pdf

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB